BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shankar S, Prasad D, Sanawar R, Das AV, Pillai MR. TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells. Sci Rep 2017;7:5500. [PMID: 28710417 DOI: 10.1038/s41598-017-05696-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Tang D, Wang G, Liu Z, Wang B, Yao M, Wang Q, Hou X, Zheng Y, Sheng C, Zhou Z. Transcriptomic analysis of the effects of the HPV18 E6E7 gene on the cell death mode in esophageal squamous cell carcinoma. Oncol Lett 2023;25:167. [PMID: 36960186 DOI: 10.3892/ol.2023.13753] [Reference Citation Analysis]
2 Hegde YM, Theivendren P, Srinivas G, Palanivel M, Shanmugam N, Kunjiappan S, Vellaichamy S, Gopal M, Dharmalingam SR. A Recent Advancement in Nanotechnology Approaches for the Treatment of Cervical Cancer. Anticancer Agents Med Chem 2023;23:37-59. [PMID: 35570521 DOI: 10.2174/1871520622666220513160706] [Reference Citation Analysis]
3 Kim TH, Lee SW. Therapeutic Application of Genome Editing Technologies in Viral Diseases. Int J Mol Sci 2022;23:5399. [PMID: 35628210 DOI: 10.3390/ijms23105399] [Reference Citation Analysis]
4 Lan T, Que H, Luo M, Zhao X, Wei X. Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy. Mol Cancer 2022;21:71. [PMID: 35277177 DOI: 10.1186/s12943-022-01550-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Fabbrizi MR, Parsons JL. Cell death mechanisms in head and neck cancer cells in response to low and high-LET radiation. Expert Rev Mol Med 2022;24. [DOI: 10.1017/erm.2021.31] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. J Clin Med 2021;10:4523. [PMID: 34640541 DOI: 10.3390/jcm10194523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
7 González Castro N, Bjelic J, Malhotra G, Huang C, Alsaffar SH. Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int J Mol Sci 2021;22:10355. [PMID: 34638696 DOI: 10.3390/ijms221910355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Udomwan P, Pientong C, Tongchai P, Burassakarn A, Sunthamala N, Roytrakul S, Suebsasana S, Ekalaksananan T. Proteomics Analysis of Andrographolide-Induced Apoptosis via the Regulation of Tumor Suppressor p53 Proteolysis in Cervical Cancer-Derived Human Papillomavirus 16-Positive Cell Lines. Int J Mol Sci 2021;22:6806. [PMID: 34202736 DOI: 10.3390/ijms22136806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Xia C, Li S, Long T, Chen Z, Chan PKS, Boon SS. Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia. Cancers (Basel) 2021;13:2691. [PMID: 34070706 DOI: 10.3390/cancers13112691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 de Almeida NAA, Ribeiro CRA, Raposo JV, de Paula VS. Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. Viruses 2021;13:822. [PMID: 34063186 DOI: 10.3390/v13050822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dhandapani H, Seetharaman A, Jayakumar H, Ganeshrajah S, Singh SS, Thangarajan R, Ramanathan P. Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro. J Gynecol Oncol 2021;32:e59. [PMID: 33908712 DOI: 10.3802/jgo.2021.32.e59] [Reference Citation Analysis]
12 Suleiman AA, Saedi WY, Muhaidi MJ. Widely used gene editing strategies in cancer treatment a systematic review. Gene Reports 2021;22:100983. [DOI: 10.1016/j.genrep.2020.100983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Bello-Rios C, Montaño S, Garibay-Cerdenares OL, Araujo-Arcos LE, Leyva-Vázquez MA, Illades-Aguiar B. Modeling and Molecular Dynamics of the 3D Structure of the HPV16 E7 Protein and Its Variants. Int J Mol Sci 2021;22:1400. [PMID: 33573298 DOI: 10.3390/ijms22031400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Scott TA, Morris KV. Designer nucleases to treat malignant cancers driven by viral oncogenes. Virol J 2021;18:18. [PMID: 33441159 DOI: 10.1186/s12985-021-01488-1] [Reference Citation Analysis]
15 Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, Naeem H, Ullah MO, Yameen M, Mukhtiar MS, Zafar F. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci 2020;263:118525. [PMID: 33031826 DOI: 10.1016/j.lfs.2020.118525] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
16 Montaño-Samaniego M, Bravo-Estupiñan DM, Méndez-Guerrero O, Alarcón-Hernández E, Ibáñez-Hernández M. Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters. Front Oncol 2020;10:605380. [PMID: 33381459 DOI: 10.3389/fonc.2020.605380] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
17 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
18 Lin Y, Chen Z, Hu C, Chen Z, Zhang L. Recent progress in antitumor functions of the intracellular antibodies. Drug Discovery Today 2020;25:1109-20. [DOI: 10.1016/j.drudis.2020.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Zheng N, Li L, Wang X. Molecular mechanisms, off-target activities, and clinical potentials of genome editing systems. Clin Transl Med 2020;10:412-26. [PMID: 32508055 DOI: 10.1002/ctm2.34] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
20 Aghamiri S, Talaei S, Roshanzamiri S, Zandsalimi F, Fazeli E, Aliyu M, Kheiry Avarvand O, Ebrahimi Z, Keshavarz-Fathi M, Ghanbarian H. Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy. Expert Opin Drug Deliv 2020;17:753-66. [PMID: 32281426 DOI: 10.1080/17425247.2020.1747429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
21 Lecher JC, Didier HL, Dickson RL, Slaughter LR, Bejarano JC, Ho S, Nowak SJ, Chrestensen CA, Mcmurry JL. Utilization of a cell-penetrating peptide-adaptor for delivery of HPV protein E2 into cervical cancer cells to arrest cell growth and promote cell death.. [DOI: 10.1101/2020.01.31.928358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol 2019;10:3116. [PMID: 32038557 DOI: 10.3389/fmicb.2019.03116] [Cited by in Crossref: 112] [Cited by in F6Publishing: 118] [Article Influence: 37.3] [Reference Citation Analysis]
23 Broeders M, Herrero-Hernandez P, Ernst MPT, van der Ploeg AT, Pijnappel WWMP. Sharpening the Molecular Scissors: Advances in Gene-Editing Technology. iScience 2020;23:100789. [PMID: 31901636 DOI: 10.1016/j.isci.2019.100789] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 16.0] [Reference Citation Analysis]
24 Shankar S, Sreekumar A, Prasad D, Das AV, Pillai MR. Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design. Cancer Cell Int 2018;18:169. [PMID: 30386178 DOI: 10.1186/s12935-018-0666-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
25 Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res 2018;5:46-58. [PMID: 29277575 DOI: 10.1016/j.pvr.2017.12.006] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 17.0] [Reference Citation Analysis]